Eisai’s breast cancer drug, Halaven, was found to offer a greater benefit than competitors currently on the market by Germany’s Institute for Quality and Efficiency in Health Care (IQWiG). Not all patients will get the thumbs up, however. Read more here. (Source: PharmaTimes digital, 11/4/14).
You are here: / / Eisai’s Halaven Gets A Thumbs Up From Germany’s IQWiG